Table 1 Patient and treatment characteristics versus DPD activity levels

Age at FP-based treatment (NA = 0)

Mean [SD]

64.22 [12.11]

64.38 [13.67]

0.95*

Sex (NA = 0)

0.17

Female

67 (85.9%)

11 (14.1%)

–

Male

44 (75.86%)

14 (24.14%)

–

Cancer location (NA = 0)

0.76

Digestive

86 (81.9%)

19 (18.1%)

–

Head and Neck

5 (71.43%)

2 (28.57%)

–

Breast

20 (83.33%)

4 (16.67%)

–

0.33

Local disease

35 (87.5%)

5 (12.5%)

–

Advanced disease

76 (79.17%)

20 (20.83%)

–

DPD prescription (NA = 0)

0.59

Before FP start

89 (82.41%)

19 (17.59%)

–

During FP Treatment

22 (78.57%)

6 (21.43%)

–

Other chemotherapy before FP (NA = 0)

0.61

No

85 (82.52%)

18 (17.48%)

–

Yes

26 (78.79%)

7 (21.21%)

–

FP-based treatment (NA = 0)

0.61

Capecitabine

29 (76.32%)

9 (23.68%)

–

5-FU

58 (82.86%)

12 (17.14%)

–

Both alternatively

24 (85.71%)

4 (14.29%)

–

FP-based toxicity (NA = 4)

0.17

No

57 (52.78%)

16 (69.57%)

–

Yes

51 (47.22%)

7 (30.43%)

–

Surgery associated to FP (NA = 1)

0.31

No

31 (88.57%)

4 (11.43%)

–

Yes

79 (79%)

21 (21%)

–

Radiotherapy associated to FP (NA = 0)

0.65

No

47 (79.66%)

12 (20.34%)

–

Yes

64 (83.12%)

13 (16.88%)

–

Nb. of chemotherapy lines (NA = 1)

Median [Min-Max]

1 [1–12]

2 [1–5]

0.26**

Nb. of FP cycles (NA = 0)

Median [Min-Max]

7 [1–48]

9 [1–18]

0.39**

0.032

No

35 (34.31%)

14 (60.87%)

–

Yes

67 (65.69%)

9 (39.13%)

–

Any recurrence (NA = 0)

0.12

No

52 (46.85%)

7 (28.0%)

–

Yes

59 (53.15%)

18 (72.0%)

–